Journal
DERMATOLOGIC THERAPY
Volume 32, Issue 3, Pages -Publisher
WILEY
DOI: 10.1111/dth.12917
Keywords
psoriasis; tumor necrosis factor-alpha; vitiligo
Categories
Ask authors/readers for more resources
Infliximab is a tumor necrosis factor-alpha (TNF-a) inhibitor widely used in the treatment of moderate to severe chronic plaque psoriasis. Here, we report a case of vitiligo following infliximab administration in a patient with chronic plaque psoriasis. The case serves as a reminder of vitiligo induced by TNF-a-antagonist therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available